This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • Marketing approval received in Japan for Alunbrig ...
News

Marketing approval received in Japan for Alunbrig in the treatment of ALK fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer.- Takeda

Read time: 1 mins
Published:26th Jan 2021
Takeda Pharmaceutical Company Limited announced that it has obtained approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market Alunbrig Tablets 30 mg, 90 mg" (brigatinib, development code: AP26113) as a first and second-line therapy for the treatment of patients with unresectable, advanced or recurrent ALK fusion gene-positive non-small cell lung cancer (ALK+ NSCLC). The approval is mainly based on the results of Brigatinib-2001 (J-ALTA), a Phase II clinical trial conducted in Japan involving 72 ALK+ patients with unresectable advanced or recurrent NSCLC who progressed after treatment with an ALK tyrosine kinase inhibitor, as well as the AP26113-13-301 (ALTA-1L) global Phase III clinical trial focused on ALK+ patients with unresectable advanced or recurrent NSCLC who had not been treated with an ALK tyrosine kinase inhibitor.
Condition: NSCLC/ ALK+
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.